Advertisement
Advertisement
AMLX
Amylyx Pharmaceuticals, Inc. Common Stock
14.73
USDSponsored
-0.47
-3.09%
May 08, 15:59 UTC -4
Closed
After-Market
14.84
+0.11
+0.74%
AMLX Earnings Reports
Positive Surprise Ratio
AMLX beat 8 of 18 last estimates.
44%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.34
Implied change from Q1 26 (Revenue/ EPS)
--
/-8.11%
Implied change from Q2 25 (Revenue/ EPS)
--
/-26.09%
Amylyx Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On May 07, 2026, AMLX reported earnings of -0.37 USD per share (EPS) for Q1 26, missing the estimate of -0.33 USD, resulting in a -9.82% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -5.35% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.34 USD, with revenue projected to reach -- USD, implying an decrease of -8.11% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+296.08%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
May 07, 2026 For Q1 26
Estimate
$0.24
Actual
$0.24
Surprise
-1.96%
SIGA Technologies Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Profound Medical Corp. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.19
Surprise
+25.75%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
ZOETIS INC.
Report Date
May 07, 2026 For Q1 26
Estimate
$1.63
Actual
$1.53
Surprise
-6.19%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
NewAmsterdam Pharma Company N.V. Ordinary Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.40
Surprise
+20.32%
FAQ
What were Amylyx Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Amylyx Pharmaceuticals, Inc. Common Stock reported EPS of -$0.37, missing estimates by -9.82%, and revenue of $0.00, 0% as expectations.
How did the market react to Amylyx Pharmaceuticals, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -5.35%, changed from $16.06 before the earnings release to $15.20 the day after.
When is Amylyx Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Amylyx Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 6
analysts, Amylyx Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.34 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement